关注并星标CPHI制药在线当肿瘤患者仍在忍受数小时静脉输注时,一场颠覆传统的治疗变革已悄然落地。6月7日,默沙东皮下注射版PD-1抑制剂帕博利珠单抗正式向中国药监局提交上市申请。这不仅是中国首款申报上市的皮下注射PD-1抗体,更意味着患者未来可能仅需2分钟就能完成抗癌治疗。从"吊瓶马拉松"到"一针即走",这场效率革命将如何改写癌症治疗格局?一、技术突破:透明质酸酶如何打破皮下注射的瓶颈在深入探讨...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.